In the Pipeline's Derek Lowe reminds his readers that interesting Phase II results don't always translate into successful Phase III tests. He points to Antisoma's AS404 and GenVec's TNFerade as examples. Both companies announced that their Phase III trials were being halted after it became clear that neither was going to meet its endpoints.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.